高级检索
当前位置: 首页 > 详情页

Study of breakthrough cancer pain in an animal model induced by endothelin-1.

文献详情

资源类型:
Pubmed体系:
机构: [a]Department of Pain, The Third Xiangya Hospital and Institute of Pain Medicine, Central South University, Changsha, Hunan Province, China [b]Medical Experimental Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China [c]Department of Pathology, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China [d]Department of Orthopaedics, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China [e]Department of Pharmacology, School of Pharmacy, Sichuan Medical University, Luzhou, Sichuan Province, China [f]Visiting Professor, Central South University, Changsha, Hunan Province, China
出处:
ISSN:

关键词: Endothelin-1 BQ-123 Breakthrough cancer pain Cancer Animal model

摘要:
Cancer patients with bone metastases often suffer breakthrough pain. However, little progress has been made in the treatment of breakthrough pain and its associated mechanism(s) in the patient with cancer due to lacking of resembling and predictive animal models. We previously have demonstrated that endothelin-1 plays an important role in breakthrough cancer pain. In the present study, we have established an animal model of breakthrough cancer pain induced by endothelin-1. The animal model of breakthrough cancer pain is strictly followed the definition and meets the characteristics of breakthrough pain. The model is reliable, reproducible and easy to be produced. To our knowledge, this is the first report for establishing such an animal model. In addition, we also found that a selective ETA receptor antagonist BQ-123 could reverse endothelin-1 induced breakthrough pain. We further studied the characteristics of pain behaviors such as hind limb use score and voluntary wheel running as well as the electrophysiology of sciatic nerve fibers with the model. The murine model shows high resemblance compared to the breakthrough cancer pain in the patients with cancer clinically. It provides a platform for further study of the pathogenesis of breakthrough cancer pain and targeted intervention. Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 4 区 医学
小类 | 4 区 神经科学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 神经科学
第一作者:
第一作者机构: [a]Department of Pain, The Third Xiangya Hospital and Institute of Pain Medicine, Central South University, Changsha, Hunan Province, China
通讯作者:
通讯机构: [a]Department of Pain, The Third Xiangya Hospital and Institute of Pain Medicine, Central South University, Changsha, Hunan Province, China [e]Department of Pharmacology, School of Pharmacy, Sichuan Medical University, Luzhou, Sichuan Province, China [f]Visiting Professor, Central South University, Changsha, Hunan Province, China [*1]Department of Pain, The Third Xiangya Hospital, Central South University, 138 Tongzipo Road, Yuelu, Changsha, Hunan Province 410013, China. [*2]Department of Pharmacology, School of Pharmacy, Sichuan Medical University, 3-319 Zhongshan Road, Luzhou, Sichuan Province 646000, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43389 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号